Allurion Technologies Announces Upcoming Financial Results
Allurion Technologies, Inc. (NYSE: ALUR), a company firmly committed to combating obesity, is preparing to unveil its financial results for the third quarter of 2024. The announcement is set for November 13, 2024, an important date for stakeholders and anyone interested in the health and wellness sector.
Details About the Financial Announcement
On the day of the announcement, Allurion’s management team will host a conference call at 8:30 AM ET. This session will provide a comprehensive overview of the company’s financial performance and future business strategies. The conference call is an excellent opportunity for investors and analysts to gain insights directly from the leadership team.
How to Participate in the Conference Call
To take part in the conference call, dial (888) 330-3417 for domestic callers, or +1 646 960 0804 for international participants. Be ready to provide the Conference ID 1905455 to join the discussion. For those who prefer, a live audio webcast of the call will be accessible through the Events section of Allurion’s Investor Relations website.
Accessing the Replay
After the call, a replay will be made available. If you wish to listen to the recorded call, you can dial (800) 770 2030 and enter Access Code 1905455. Whether you are an investor, healthcare provider, or simply interested in Allurion’s mission, these resources will ensure you stay informed.
About Allurion Technologies
Allurion is a pioneering force in the fight against obesity. The company offers a unique weight loss platform that includes the Allurion Gastric Balloon – the world’s first swallowable, Procedure-less™ intragastric balloon which simplifies the weight loss journey. This innovation is complemented by the Allurion Virtual Care Suite, designed to empower both consumers and healthcare providers.
The Allurion Virtual Care Suite
Within this suite, users can access the Allurion Mobile App, which allows for seamless monitoring of personal health journeys. Healthcare providers benefit from Allurion Insights, which includes the advanced Coach Iris AI Platform that aids in personalized care delivery. An innovative Connected Scale further supports individuals on their weight loss journeys, making this an all-encompassing approach for health management.
Innovations and Future Directions
Allurion’s focus on technological advancements sets them apart in the healthcare industry. The Gastric Balloon represents a significant shift in how weight loss therapies can be administered. Furthermore, the access to comprehensive virtual care helps patients succeed regardless of the treatment method used, be it surgical, medical, or lifestyle changes.
It’s important to note that while the Allurion Gastric Balloon is a groundbreaking development in weight loss, it remains an investigational device in the United States, highlighting the company’s commitment to safety and efficacy as it explores options to bring innovative solutions to more patients.
Final Thoughts
As Allurion Technologies prepares to unveil its financial results, the focus will also be on the ongoing development of its products and services. The upcoming conference call will provide valuable insights into how the company continues to tackle obesity through innovative solutions. Stakeholders are encouraged to actively participate and stay updated on the transformative impact of Allurion on global health.
Frequently Asked Questions
What are the details of the upcoming financial results announcement?
Allurion Technologies will report its third-quarter financial results on November 13, 2024, at 8:30 AM ET via a conference call.
How can I listen to the conference call?
Participants can dial (888) 330-3417 or +1 646 960 0804 using Conference ID 1905455, or join via the live audio webcast on Allurion's Investor Relations website.
What innovations does Allurion offer in weight loss solutions?
Allurion provides the Allurion Gastric Balloon and the Allurion Virtual Care Suite, which includes various tools and applications to assist both patients and healthcare providers.
Is the Allurion Gastric Balloon available in the U.S.?
Currently, the Allurion Gastric Balloon is considered an investigational device in the United States.
What is the significance of the Conference ID 1905455?
The Conference ID is necessary for participants to join the conference call and access the discussion on the financial results.